Taiho's Lytgobi gets US FDA approval for previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma

Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced that the US Food and Drug Administration (FDA) has approved Lytgobi tablets for the treatment of adult patients with previously treated